TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Pfizer ( (PFE) ) is now available.
On November 21, 2025, Pfizer Inc. completed a significant public offering of various notes totaling $5 billion, with maturities ranging from 2027 to 2065. This financial move, conducted under a shelf registration statement, involved major financial institutions as underwriters and is expected to impact Pfizer’s financial strategy and market positioning.
The most recent analyst rating on (PFE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.
Spark’s Take on PFE Stock
According to Spark, TipRanks’ AI Analyst, PFE is a Neutral.
Pfizer’s overall stock score reflects strong valuation and income potential, supported by a high dividend yield and attractive P/E ratio. However, financial performance is challenged by declining revenue and cash flow, and technical indicators suggest weak momentum. The earnings call highlighted strategic initiatives but also underscored ongoing challenges, particularly in COVID-19 product revenues and legal issues.
To see Spark’s full report on PFE stock, click here.
More about Pfizer
Pfizer Inc. is a leading pharmaceutical company known for its development and manufacturing of healthcare products, including vaccines and medicines. The company operates globally, focusing on innovation in the pharmaceutical industry to address health challenges.
Average Trading Volume: 66,631,816
Technical Sentiment Signal: Hold
Current Market Cap: $141.5B
See more data about PFE stock on TipRanks’ Stock Analysis page.